EIF5A2 and urinary bladder carcinoma: For example, GC7 combination therapy enhances the therapeutic efficacy of doxorubicin in bladder cancer and estrogen-negative breast cancer cells by inhibiting eIF5A2 activation and preventing the EMT [15, 16].